W2O symplur

News

W2O has chalked up its fifth acquisition in less than a year with a deal to buy healthcare social media analytics company Symplur.

News

Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.